MedEnrich | Página principal
Continue Watching
últimos vidéos
últimos vidéos
Brightcove Home Latest Listing
Cáncer de mama
Cáncer de mama
Brightcove Cards Listing
Cáncer de próstata
Brightcove Cards Listing
Mieloma múltiple
Mieloma múltiple
Brightcove Cards Listing
Popular en MedEnrich
Popular in Sin nombre
Cáncer de mama3m 36s
Tumor Infiltrating Lymphocytes as Predictive Biomarker in Breast Cancer
Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.
1
Tumor Infiltrating Lymphocytes as Predictive...
1
SABCS Update 2022
Cáncer de mama8m 55s
Understanding HER-2 Low Breast Cancer Entity & Treatment Strategy
Tumors with a HER-2 immunohistochemistry (IHC) score of 1 + or 2 + and a negative molecular reflex test have been classified as HER2-low Breast Cancers.
1
Understanding HER-2 Low Breast Cancer Entity &...
Cancer de prostata11m 38s
Treatment Intensification in Metastatic Castration Sensitive Prostate Cancer
PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.
1
Treatment Intensification in Metastatic Castration...
Cáncer de mama8m 46s
Expert Perspective - How I Treat Metastatic Her2 Positive Breast Cancer
Anti-HER2 directed therapy remains the cornerstone of care for individuals with HER2-positive metastatic breast cancer (MBC).
1
Expert Perspective - How I Treat Metastatic Her2...
Oncology1m 36s
Enhancing Global Access to Cancer Medicines
Over the last decade we have seen emergence of increasing novel therapies like targeted therapy and immunotherapy & this has changed the natural history of disease for patients living with cancer including those with advanced disease.
1
Enhancing Global Access to Cancer Medicines
Mieloma múltiple7m 42s
MRD Assesment in Multiple Myeloma -Ready for Prime Time
Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.
1
MRD Assesment in Multiple Myeloma -Ready for Prime...
Myelodysplastic Syndromes17m 59s
Genomics of AML -Therapeutic and Prognostic Implications
~40% of AML patients have targetable mutations. Younger patients often have FLT3-ITD or FLT3- TKD mutation. Mutations IDH-1 , IDH-2 & t-53 mutations are more common in elderly patients.
1
Genomics of AML -Therapeutic and Prognostic...
Myelodysplastic Syndromes3m 14s
Low Risk MDS - Key Practice Points
Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features.
1
Low Risk MDS - Key Practice Points
Cancer de prostata6m 59s
Managing Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPC
1
Managing Nonmetastatic Castration-Resistant...
Seminarios web anteriores
Seminarios web anteriores
Webinar Cards Listing
Artículos
Artículos
Medbytes Cards Listing
